Trial reportClinical ophthalmology (Auckland, N.Z.)2026
Comparison of Anterior Chamber Depth Changes of Two Hydrophobic Acrylic Intraocular Lenses in the Capsular Bag: A Prospective, Randomized, Contralateral Eye, Multicenter Study.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate postoperative changes in anterior chamber depth (ACD), intraocular lens (IOL) tilt, and decentration of the Clareon IOL in a capsular bag compared with those of the AcrySof IQ IOL. Patients and Methods: In this prospective multicenter study, we randomly assigned patients scheduled for bilateral cataract surgery to receive the Clareon IOL in one eye and the AcrySof IQ IOL (both manufactured by Alcon Vision LLC, Fort Worth, TX, USA) in the fellow eye. ACD, IOL tilt, decentration, visual acuity, and subjective refraction were measured 1 day, 1 week, and 1, 3, and 6 months after surgery. The primary objective was to demonstrate the equivalence between Clareon and AcrySof IQ IOL regarding ACD changes from 1 day to 6 months. Results: Overall, 64 eyes from 32 patients were included. The Clareon IOL met the equivalence criteria; the 95% confidence interval for the difference in ACD change (0.026 mm; 95% confidence interval, -0.02 to 0.072) was within -0.15 and 0.15 mm. At 6 months, the means ± standard deviations of the ACD, IOL tilt, and decentration were 4.26 ± 0.30 mm, 4.3 ± 1.9°, and 0.17 ± 0.11 mm for Clareon IOL, and 4.23 ± 0.30 mm, 4.0 ± 1.9°, and 0.16 ± 0.11 mm for AcrySof IQ IOL, respectively (P = 0.052, 0.421, and 0.916, respectively). The subjective spherical equivalence at 6 months was -0.01 ± 1.03 and -0.08 ± 0.90 D for Clareon IOL and AcrySof IQ IOL, respectively. Conclusion: The Clareon IOL was equivalent to the AcrySof IQ IOL regarding ACD changes from 1 day to 6 months. No significant differences were observed in ACD, IOL tilt, or refractive outcomes at 6 months between the two IOLs in the same patients. Both IOLs showed good stability in the bag through 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.